TLXTelix Pharma

Telix Pharmaceuticals shares fell sharply after announcing a major US$1.65 billion acquisition of ITM Isotope Technologies, with investors reacting negatively to the scale and cost of the deal.

The ASX Health Care sector rose strongly on the same day, lifting TLX as part of a broad sector rotation into health stocks.

TLX fell sharply in sympathy with a broader US market sell-off and weakness in the Australian healthcare sector, with no company-specific news to explain the move.

Positive analyst commentary and sector flows into ASX healthcare names, with Telix highlighted as a recovering growth share, likely drove the move.

The stock drop was part of a broader selloff in ASX 200 shares, with Telix Pharmaceuticals among the biggest losers for the day.

Telix Pharmaceuticals announced a radiopharma collaboration with Regeneron, a multi-billion dollar deal, driving the share price up 7.72%.

Telix Pharmaceuticals shares rose on the announcement of a major radiopharma partnership with Regeneron, including a $40 million upfront payment.

Telix Pharmaceuticals shares continued to bounce off lows, likely driven by a positive analyst mention and biotech sector interest despite a recent FDA-related drop.

Telix shares bounced off lows after a recent drop, despite a favorable US FDA update that was followed by buying interest.

Positive Phase 3 trial results for Telix's prostate cancer therapy triggered the stock surge.

Telix Pharmaceuticals shares fell 5.12% on March 8, 2026, ahead of the positive Phase 3 trial results announced on March 10, likely due to profit-taking or de-risking ahead of the binary readout.

Telix's expansion of its AI-driven imaging push, highlighted in a research partnership announced on the event date, likely drove the stock up.

Telix Pharmaceuticals' shares surged following strong 2026 guidance, a shelf filing, and a TLX101-Px milestone, as reported in news articles around the date.

Despite positive news of 2026 guidance, a shelf filing, and a TLX101-Px milestone, the stock fell 6.04% on the event date.

Telix Pharmaceuticals shares fell after a significant rally on Friday following FY25 results, likely due to profit-taking and market digestion of the news.

Telix Pharmaceuticals shares jumped 14.24% after reporting strong FY2025 results with 56% revenue growth and a positive FY2026 outlook.

Telix Pharmaceuticals fell amid a broad market downturn that pushed 13 ASX 200 stocks to multi-year lows, with no stock-specific adverse news.

Telix Pharmaceuticals shares bounced off multi-year lows amid broader ASX 200 market momentum and mention as a potentially undervalued stock, with no company-specific catalyst identified.

The stock fell sharply following a prior 55% sell-off, despite emerging China regulatory progress and positive full-year guidance updates.

Telix Pharmaceuticals fell 6.61% on December 16, 2025, due to news of a potential US class action lawsuit over alleged disclosure failings, exacerbating an ongoing steep decline.

No direct news found; likely driven by positive sector sentiment in healthcare or a company-specific announcement not captured in the provided articles.